VICTOZA 6mg/ml Price

Overview

Welcome to Dwaey, specifically on VICTOZA 6mg/ml page.
This medicine contains an important and useful components, as it consists of
Liraglutideis available in the market in concentration

Name

Liraglutide

Precaution

CHF, inflammatory bowel disease, diabetic gastroparesis, preexisting thyroid disease. Increased risk of hypoglycaemia w/ sulfonylurea. Hepatic impairment. Do not administer via IV or IM. May affect ability to drive or operate machinery. Childn <18 yr. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide. Not for use in patients with type 1 diabetes mellitus or for treatment of diabetic ketoacidosis. Resting heart rate may increase by 2 to 3 bpm; up to 10-20 bpm increases also reported. Not a substitute for insulin. Lactation: Unknown if excreted in human milk; either discontinue drug or nursing

Indication

Type 2 diabetes

Contra indication

Do not use in patients with a prior serious hypersensitivity reaction to any of the product components. Type 1 DM, diabetic ketoacidosis. Severe renal impairment & end-stage renal disease. Pregnancy & lactation. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)

Side Effect

>10% Nausea (26%),Diarrhea (17%),Vomiting (11%) 1-10% Constipation (10%),Headache (9%),Antiliraglutide antibodies (7%),Injection-site reactions (2%) <1% (Victoza) Urticaria,Upper respiratory tract infection,UTI,Dizziness,Sinusitis,Nasopharyngitis,Back pain,Hypertension,Hypoglycemia (mostly in combination therapy),Pancreatitis,Papillary thyroid carcinoma,Thyroid C-cell hyperplasia

Pregnancy Category ID

3

Mode of Action

Incretin mimetic; analogue of human glucagonlike peptide-1 (GLP-1); acts as GLP-1 receptor agonist to increase insulin secretion in the presence of elevated blood glucose; delays gastric emptying to decrease postprandial glucose; also decreases glucagon secretion.

Interaction

Oral Contraceptives: Liraglutide lowered ethinyloestradiol and levonorgestrel Cmax by 12% and 13%, respectively, following administration of a single dose of an oral contraceptive product. Tmax was delayed by 1.5 hrs with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinyloestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide. Increased risk of hypoglycaemia when used w/ insulin secretagogues (e.g. sulfonylurea, meglitinide). May affect absorption of concomitantly administered oral drugs due to slow gastric emptying. Insulin: Combination of Liraglutide with insulin has not been evaluated.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration